0001193125-16-759457.txt : 20161104 0001193125-16-759457.hdr.sgml : 20161104 20161104060403 ACCESSION NUMBER: 0001193125-16-759457 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161104 DATE AS OF CHANGE: 20161104 EFFECTIVENESS DATE: 20161104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HORIZON PHARMACEUTICAL LLC CENTRAL INDEX KEY: 0001070698 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860883978 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-25571 FILM NUMBER: 161973535 BUSINESS ADDRESS: STREET 1: 7 HAMILTON LANDING STREET 2: SUITE 100 CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-408-6200 MAIL ADDRESS: STREET 1: 7 HAMILTON LANDING STREET 2: SUITE 100 CITY: NOVATO STATE: CA ZIP: 94949 FORMER COMPANY: FORMER CONFORMED NAME: Raptor Pharmaceutical Corp DATE OF NAME CHANGE: 20090929 FORMER COMPANY: FORMER CONFORMED NAME: Raptor Pharmaceutical Corp. DATE OF NAME CHANGE: 20090929 FORMER COMPANY: FORMER CONFORMED NAME: TorreyPines Therapeutics, Inc. DATE OF NAME CHANGE: 20061003 15-12G 1 d268629d1512g.htm 15-12G 15-12G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

000-25571

(Commission File Number)

 

 

HORIZON PHARMACEUTICAL LLC

(Exact name of registrant as specified in its charter)

 

 

7 Hamilton Landing, Suite 100

Novato, CA 94949

(415) 408-6200

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.001 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)    ☒
Rule 12g-4(a)(2)    ☐
Rule 12h-3(b)(1)(i)    ☒
Rule 12h-3(b)(1)(ii)    ☐
Rule 15d-6    ☐

Approximate number of holders of record as of the certification or notice date: 1

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Horizon Pharmaceutical LLC (f/k/a Raptor Pharmaceutical Corp.) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: November 4, 2016     HORIZON PHARMACEUTICAL LLC
    By:   /s/ Paul W. Hoelscher
      Name: Paul W. Hoelscher
      Title: Executive Vice President, Chief Financial Officer

[Signature Page to Form 15]